About astellas pharma inc. - ALPMY
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
ALPMY At a Glance
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho
Tokyo, Tokyo 103-8411
| Phone | 81-3-3244-3000 | Revenue | 12.54B | |
| Industry | Pharmaceuticals: Major | Net Income | 332.88M | |
| Sector | Health Technology | 2025 Sales Growth | 12.96% | |
| Fiscal Year-end | 03 / 2026 | Employees | 13,643 | |
| View SEC Filings |
ALPMY Valuation
| P/E Current | 12.837 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 52.033 |
| Price to Sales Ratio | 1.386 |
| Price to Book Ratio | 1.711 |
| Price to Cash Flow Ratio | 13.14 |
| Enterprise Value to EBITDA | 7.505 |
| Enterprise Value to Sales | 1.785 |
| Total Debt to Enterprise Value | 0.28 |
ALPMY Efficiency
| Revenue/Employee | 919,438.946 |
| Income Per Employee | 24,399.00 |
| Receivables Turnover | 2.903 |
| Total Asset Turnover | 0.546 |
ALPMY Liquidity
| Current Ratio | 1.132 |
| Quick Ratio | 0.852 |
| Cash Ratio | 0.177 |
ALPMY Profitability
| Gross Margin | 74.588 |
| Operating Margin | 13.37 |
| Pretax Margin | 1.647 |
| Net Margin | 2.654 |
| Return on Assets | 1.45 |
| Return on Equity | 3.222 |
| Return on Total Capital | 2.031 |
| Return on Invested Capital | 2.339 |
ALPMY Capital Structure
| Total Debt to Total Equity | 61.925 |
| Total Debt to Total Capital | 38.243 |
| Total Debt to Total Assets | 28.06 |
| Long-Term Debt to Equity | 43.233 |
| Long-Term Debt to Total Capital | 26.699 |